Stock Track | Nuvation Bio Soars 5.50% in Post-Market on Positive Analyst Ratings and Maintained Buy Recommendations

Stock Track
03/04

Nuvation Bio Inc. (NUVB) experienced a significant surge of 5.50% during post-market trading on Tuesday, reflecting positive investor sentiment following recent analyst actions.

The stock's upward movement appears to be driven by favorable analyst coverage, including Wedbush maintaining its Buy rating on Nuvation Bio with a price target of $11.00. Analyst David Nierengarten from Wedbush continued to express confidence in the company's prospects despite broader market challenges in the healthcare sector.

Additionally, market data indicates that Nuvation Bio maintains an average rating of "Buy" among analysts, with a mean price target of $11.60 according to FactSet polling. This positive analyst sentiment, particularly the maintained Buy rating from Wedbush with a target significantly above current trading levels, likely contributed to the stock's post-market surge as investors responded to the optimistic outlook.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10